Source: Intervet/Schering-Plough Animal Health news release
Intervet/Schering-Plough Animal Health announces the introduction of Nuflor Gold® (florfenicol), an antibiotic for the treatment of bovine respiratory disease (BRD) associated with four major bovine respiratory pathogens. The product has been approved by the FDA for the treatment of BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and now, Mycoplasma bovis. BRD is a major health problem in cattle and the most significant cause of economic loss for the cattle industry.
"NUFLOR GOLD is the first florfenicol product approved to treat BRD associated with Mycoplasma bovis,” said Dr. Joe Roder, DVM, Intervet/Schering-Plough Animal Health. "BRD is a serious condition, and most cattle affected by BRD will suffer significantly unless the disease is treated effectively.”
Florfenicol is generally considered a bacteriostatic drug, but it exhibits bactericidal activity against certain bacterial species. Although the correlation between in vitro susceptibility data and clinical effectiveness is unknown, in vitro studies demonstrated that florfenicol is active against the BRD pathogens Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma bovis, and that florfenicol exhibits bactericidal activity against strains of Mannheimia haemolytica and Histophilus somni.
NUFLOR GOLD is available by prescription only. For more information, visit www.nuflorgold.com.